drugset / Trial / NCT06885710
HBV-Specific TCR-T Cell Therapy Combined With Nucleos(t)Ide Analogues in Chronic Hepatitis B Patients
NaSingle-groupOpen-labelTreatment
Summary
This is a open-label study to evaluate the safety and efficacy of autologous T-cells transfected with messenger ribonucleic acid (mRNA) encoding Hepatitis-B virus (HBV) antigen specific T cell receptor (TCR) in combination with nucleos(t)ide analogues (NAs) in HBeAg-positive and negative chronic hepatitis B patients.
Timeline
- Start
- 2024-12-31
- Primary completion
- 2027-12-01
- Completion
- 2028-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LioCyx-M | Cell therapy | 500000 cells/kg | Other |
| Subject | LioCyx-M | Cell therapy | 5e+07 cells/kg | Other |